San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Abintus Bio is raising $15,652,623.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Nicholas Boyle played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Abintus Bio
Abintus Bio is leading the field of in vivo immune cell reprogramming using clinically proven technologies and manufacturing processes. We are pursuing In Vivo CAR-X products that modulate innate and adaptive immune effector cells from within their native environment to enhance patient access and outcomes. Abintus Bio, Inc. is a San Diego-based, preclinical stage gene therapy company focused on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies. Abintus is leveraging over $275 million of prior investment in the advancement of in vivo retroviral technology and has over 83 years of collective experience and know-how with the engineering, manufacturing and development of in vivo retroviral vectors, including the treatment of over 350 patients through Phase 3 registration trials and late-stage commercial launch planning.

To learn more about Abintus Bio, visit http://abintusbio.com/

Contact:
Nicholas Boyle, President and Chief Executive Officer
858-866-9795
https://www.linkedin.com/in/nicholasboyle/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved